CN105343636A - Dual-purpose medical and edible composition with blood fat reducing function and preparing method of dual-purpose medical and edible composition - Google Patents
Dual-purpose medical and edible composition with blood fat reducing function and preparing method of dual-purpose medical and edible composition Download PDFInfo
- Publication number
- CN105343636A CN105343636A CN201510913579.5A CN201510913579A CN105343636A CN 105343636 A CN105343636 A CN 105343636A CN 201510913579 A CN201510913579 A CN 201510913579A CN 105343636 A CN105343636 A CN 105343636A
- Authority
- CN
- China
- Prior art keywords
- extract
- dual
- medicine
- parts
- blood fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 210000004369 blood Anatomy 0.000 title claims abstract description 34
- 239000008280 blood Substances 0.000 title claims abstract description 34
- 230000001603 reducing effect Effects 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title abstract description 3
- 235000013557 nattō Nutrition 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 20
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 14
- 229940094952 green tea extract Drugs 0.000 claims abstract description 14
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 14
- 230000000055 hyoplipidemic effect Effects 0.000 claims description 32
- 238000002360 preparation method Methods 0.000 claims description 19
- 241000237636 Pheretima Species 0.000 claims description 17
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 13
- 229930003944 flavone Natural products 0.000 claims description 13
- 150000002212 flavone derivatives Chemical class 0.000 claims description 13
- 235000011949 flavones Nutrition 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 13
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 13
- 229920001661 Chitosan Polymers 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 241000243684 Lumbricus Species 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000012467 final product Substances 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000004386 Erythritol Substances 0.000 claims description 5
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 5
- 229940009714 erythritol Drugs 0.000 claims description 5
- 235000019414 erythritol Nutrition 0.000 claims description 5
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 4
- 244000063299 Bacillus subtilis Species 0.000 claims description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- -1 hydroxyl isomaltulose Chemical compound 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000019605 sweet taste sensations Nutrition 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 17
- 210000002966 serum Anatomy 0.000 abstract description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 2
- 238000010008 shearing Methods 0.000 abstract 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 abstract 1
- 235000017491 Bambusa tulda Nutrition 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 244000082204 Phyllostachys viridis Species 0.000 abstract 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 abstract 1
- 241000219780 Pueraria Species 0.000 abstract 1
- 239000011425 bamboo Substances 0.000 abstract 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 235000020717 hawthorn extract Nutrition 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 38
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 13
- 108010023302 HDL Cholesterol Proteins 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 201000005577 familial hyperlipidemia Diseases 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 206010020590 Hypercalciuria Diseases 0.000 description 4
- 229940086319 nattokinase Drugs 0.000 description 4
- 108010073682 nattokinase Proteins 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000011629 hyperlipidemia animal model Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000545442 Radix Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038372 Renal arteriosclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- KYAKGJDISSNVPZ-UHFFFAOYSA-N etofylline clofibrate Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KYAKGJDISSNVPZ-UHFFFAOYSA-N 0.000 description 1
- 229950009036 etofylline clofibrate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention belongs to the field of health-care products and particularly relates to a dual-purpose medical and edible composition with a blood fat reducing function and a preparing method of the dual-purpose medical and edible composition. The dual-purpose medical and edible composition with the blood fat reducing function is mainly prepared from natto extract, earthworm extract, bamboo leaf flavonoid, hawthorn extract, pueraria extract, ginseng extract, green tea extract, chitosan oligosaccharide and a sweetening agent. The dual-purpose medical and edible composition with the blood fat reducing function can obviously reduce the TC and TG content of serum of hyperlipidemia rats, and can also obviously reduce the high shearing viscosity, medium shearing viscosity and low shearing viscosity of the blood of the hyperlipidemia rats, and thus it is indicated that the dual-purpose medical and edible composition with the blood fat reducing function has the obvious blood fat reducing effect. In addition, the composition is definite in effective ingredient, controllable in quality, low in toxic and side effect, high in safety and suitable for being taken in a long term and is ideal blood fat reducing health-care food.
Description
Technical field
The invention belongs to field of health care products, be specifically related to a kind of medicine-food dual-purpose composition with hypolipemic function and preparation method thereof.
Background technology
Blood fat is the general name of neutral fat (triglyceride and cholesterol) in blood plasma and lipoid (phospholipid, glycolipid, sterin, steroid), is extensively present in human body.Blood fat is a kind of important material in human body, has many important functions, but can not exceed certain scope.Hyperlipidemia refers to blood cholesterol (TC) and/or triglyceride (TG) is too high or HDL-C (HDL-C) is too low.At present, the patient of hyperlipidemia is very general.The harm of hyperlipidemia is: if hyperlipoidemia, easily cause " blood is thick ", blood vessel wall deposits, and forms little speckle gradually, and these " specklees " increase, increase, artery-clogging gradually, and make blood flow slack-off, time serious, blood flow is interrupted.If this situation occurs in heart, just cause coronary heart disease; Occur in brain, just there will be apoplexy; If blocking optical fundus blood vessel, visual deterioration, blind will be caused; If occur in kidney, renal arteriosclerosis will be caused, renal failure; Occur in lower limb, there will be limb necrosis, fester.In addition, hyperlipidemia can cause hypertension, brings out cholelithiasis, pancreatitis, increases the weight of hepatitis, causes the disease such as male sexual disorder, senile dementia, serious harm human health.
The clinical Western medicine for blood fat reducing mainly contains fenofibrate, etofylline clofibrate, furaprbal, Statins etc. at present, said medicine is all take Statins as main component, although it effectively can reduce serum cholesterol content, statins can cause muscle changes, is unfavorable for long-term taking.In recent years, studies have found that Chinese patent medicine has side effect for blood fat reducing low, lipid-lowering effect is good, the advantage that safety is high, is subject to the favor of increasing hypercalcinuria patient.
Chinese patent application 201210226426.X discloses a kind of by the health product of blood fat, described health product are made up of raw materials such as nattokinase, hirudin, Pheretima, Fructus Lycii, Fructus Crataegi, Radix Salviae Miltiorrhizae and the Radixs Astragali, it is little that the blood fat reducing health products prepared has toxic and side effects, can blood fat be reduced, make blood viscosity reach effect of normal range.
Chinese patent application 201210423854.1 discloses a kind of Chinese medicine of blood fat reducing, described Chinese medicine is made up of raw materials such as Radix Scutellariae, Fructus Crataegi, Rhizoma Alismatis, fructus lycii, Pheretima, nattokinase, Radix Salviae Miltiorrhizae, Bulbus Lilii powder, the Radix Paeoniae Alba, Radix Polygoni Multiflori, Rhizoma Polygonati and Semen Cassiae, and the Chinese medicine prepared effectively can prevent effect of cerebral thrombosis, dizzy, neurasthenia, blood fat reducing.
Summary of the invention
The object of the present invention is to provide medicine-food dual-purpose composition with hypolipemic function that a kind of determined curative effect, toxic and side effects are little, safety is high and preparation method thereof.
The invention provides a kind of medicine-food dual-purpose composition with hypolipemic function, comprise following component and parts by weight thereof:
Natto extract 10-20 part, Pheretima extract 10-20 part, Folium Bambosae flavone 8-16 part, Fructus Crataegi extract 2-6 part, Radix Puerariae extract 0.5-3 part, Radix Ginseng extract 0.1-2 part, green tea extract 0.1-2 part, oligochitosan 4-14 part and sweeting agent 40-60 part.
Further, the medicine-food dual-purpose composition described in hypolipemic function comprises following component and parts by weight thereof:
Natto extract 13 parts, Pheretima extract 12 parts, Folium Bambosae flavone 10 parts, Fructus Crataegi extract 3 parts, Radix Puerariae extract 1 part, Radix Ginseng extract 0.5 part, green tea extract 0.5 part, oligochitosan 8 parts and sweeting agent 52 parts.
Further, the preparation method of described natto extract is:
S1 adds Semen sojae atricolor weight 2-4 times of water soaking 10-16h after being cleaned by Semen sojae atricolor;
The Semen sojae atricolor subpackage that step S1 obtains by S2, sterilizing 30min under 105 DEG C of conditions, accesses the bacillus subtilis of above-mentioned Semen sojae atricolor amount 0.5-2%, stirs, then at temperature is 37-39 DEG C, cultivate 35-45h, obtain natto when rear product temperature subject to sterilization is cooled to 30-35 DEG C;
Physiological saline solution joins in the natto that step S2 obtains by S3 under the aseptic condition of 25 DEG C-30 DEG C, the addition of normal saline be the 1-2 of natto weight doubly, stir 25-35min, filter, obtain eluent;
S4 by concentration be the eluent that obtains of ascorbic acid solution and the step S3 of 2-8% by volume 1:1 mix, adjust ph is to 7.0-7.2, pre-freeze 5-7h at being placed in-8 ~-6 DEG C, then put into temperature and be-45 DEG C, vacuum is 10-15Pa, and heating shelf temperature is in 30 DEG C of dry machines frozen after dry 10-20h, pulverizes under the aseptic condition of 0-8 DEG C, cross 40-80 order, to obtain final product.
Further, the preparation method of described Pheretima extract is:
Lumbricus is cleaned by S1, and adding pressure is that after placing 3-5h in the pressure reduction vessel of 90-95kPa, cleaning drains;
Adding above-mentioned Lumbricus weight 3-5 times concentration in the Lumbricus that S2 obtains toward step S1 is the sodium chloride solution of 0.5-2%, after then stirring 3-6min in refiner, leaves standstill 3-5h, obtains homogenate;
It is centrifugal 8-12min in the centrifuge of 9000-10000rpm that the homogenate that step S2 obtains by S3 adds rotating speed, stay supernatant, by the ultrafilter membrane of supernatant by molecular cut off 8k, it is-60 DEG C ~-70 DEG C in temperature, vacuum is freezing 2-4h under 15-20pa condition, then be 40-50 DEG C of dry 10-12h in temperature, obtain final product.
Further, described sweeting agent is one in Sorbitol, erythritol, xylitol and hydroxyl isomaltulose or its mixture.
Further, described medicine-food dual-purpose composition makes tablet, capsule, pill, granule or powder.
The medicine-food dual-purpose composition with hypolipemic function provided by the invention has blood fat reducing function significantly, proves: the medicine-food dual-purpose composition with blood fat reducing function provided by the invention has significant blood fat reducing function through test.Compared with model group, test serum serum TC and TG content that 1 group extremely significantly can be reduced hyperlipemia rat (P < 0.01), simultaneously, compared with model group, test 1 group can extremely significantly (P < 0.01) reduce hyperlipemia rat blood high shear viscosity, in cut viscosity and lowly cut viscosity, prove that the medicine-food dual-purpose composition with hypolipemic function provided by the invention has lipid-lowering effect significantly.
Further, find through clinical trial, the medicine-food dual-purpose composition with blood fat reducing function provided by the invention to the total effective rate of the treatment of hyperlipidemia exception person up to 81.8%, for vast hypercalcinuria patient provides a kind of determined curative effect, the significant lipid-lowering health food of therapeutic effect.
In addition, present invention also offers a kind of preparation method with the medicine-food dual-purpose composition of hypolipemic function, comprise the following steps:
S1, by natto extract, Pheretima extract, Fructus Crataegi extract, Radix Puerariae extract, Radix Ginseng extract and green tea extract mix homogeneously, crosses 18-25 mesh sieve, obtains mixing fine powders;
S2 adds Folium Bambosae flavone, oligochitosan and sweeting agent mix homogeneously toward the mixing fine powders that step S1 obtains, and to obtain final product.
Further, present invention also offers the described medicine-food dual-purpose composition with hypolipemic function and prepare the application had in the health food of effect for reducing blood fat.
Compared with prior art, the medicine-food dual-purpose composition with hypolipemic function provided by the invention has following advantage:
(1) the medicine-food dual-purpose composition effective ingredient with hypolipemic function provided by the invention is clear and definite, quality controllable, and lipid-lowering effect is remarkable, for vast hypercalcinuria patient provides a kind of new medicine;
(2) the medicine-food dual-purpose composition toxic and side effects with hypolipemic function provided by the invention is low, safety is high, and being applicable to long-term taking, is a kind of desirable blood fat reducing healthcare food.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.Composition of the present invention is commercially available conventional products, such as: Fructus Crataegi extract, Radix Puerariae extract, Radix Ginseng extract and green tea extract are all purchased from Shanxi Jiahe Plant Chemical Co., Ltd.; Folium Bambosae flavone is purchased from Guangdong Tian Kang QINGZHU biological food company limited; Oligochitosan is purchased from Zhaoqing Longline Biotechnology Co., Ltd..
embodiment 1,the preparation of natto extract
S1 adds Semen sojae atricolor weight 3 times of water soaking 12h after being cleaned by Semen sojae atricolor;
The Semen sojae atricolor subpackage that step S1 obtains by S2, sterilizing 30min under 105 DEG C of conditions, accesses the bacillus subtilis of above-mentioned Semen sojae atricolor amount 1%, stirs when rear product temperature subject to sterilization is cooled to 30 DEG C, be then 38 DEG C in temperature and cultivate 40h, obtain natto;
Physiological saline solution joins in the natto that step S2 obtains by S3 under the aseptic condition of 25 DEG C-30 DEG C, and the addition of normal saline is 1 times of natto weight, stirs 30min, filters, obtains eluent;
S4 by concentration be 5% the eluent that obtains of ascorbic acid solution and step S3 by volume 1:1 mix, adjust ph to 7.0, pre-freeze 6h at being placed in-8 DEG C, then put into temperature and be-45 DEG C, vacuum is 13.3Pa, and heating shelf temperature is in 30 DEG C of dry machines frozen after dry 16h, pulverizes under the aseptic condition of 8 DEG C, cross 80 orders, to obtain final product.
embodiment 2,the preparation of Pheretima extract
It is that after placing 4h in the pressure reduction vessel of 92kPa, cleaning drains that Lumbricus is added pressure by S1;
Adding above-mentioned Lumbricus weight 4 times of concentration in the Lumbricus that S2 obtains toward step S1 is the sodium chloride solution of 1%, after then stirring 5min in refiner, leaves standstill 4h, obtains homogenate;
It is centrifugal 10min in the centrifuge of 9800rpm that the homogenate that step S2 obtains by S3 adds rotating speed, stays supernatant, by the ultrafilter membrane of supernatant by molecular cut off 8k, be-60 DEG C in temperature, vacuum is freezing 3h under 15pa condition, is then 50 DEG C of dry 12h in temperature, obtains final product.
embodiment 3,
Prescription:
Natto extract 10 parts, Pheretima extract 10 parts, Folium Bambosae flavone 8 parts, Fructus Crataegi extract 2 parts, Radix Puerariae extract 0.5 part, Radix Ginseng extract 0.1 part, green tea extract 0.1 part, oligochitosan 4 parts and Sorbitol 4 parts.
Preparation method:
S1, by natto extract, Pheretima extract, Fructus Crataegi extract, Radix Puerariae extract, Radix Ginseng extract and green tea extract mix homogeneously, crosses 18 mesh sieves, obtains mixing fine powders;
S2 adds Folium Bambosae flavone, oligochitosan and sweeting agent mix homogeneously toward the mixing fine powders that step S1 obtains, and adds corresponding adjuvant and makes capsule.
embodiment 4,
Prescription:
Natto extract 13 parts, Pheretima extract 12 parts, Folium Bambosae flavone 10 parts, Fructus Crataegi extract 3 parts, Radix Puerariae extract 1 part, Radix Ginseng extract 0.5 part, green tea extract 0.5 part, oligochitosan 8 parts and erythritol 52 parts.
Preparation method is similar to Example 1, adds corresponding adjuvant and makes tablet.
embodiment 5,
Prescription:
Natto extract 20 parts, Pheretima extract 20 parts, Folium Bambosae flavone 16 parts, Fructus Crataegi extract 6 parts, Radix Puerariae extract 3 parts, Radix Ginseng extract 2 parts, green tea extract 2 parts, oligochitosan 14 parts and xylitol 60 parts.
Preparation method is similar to Example 1, adds corresponding adjuvant and makes granule.
comparative example 1,
Prescription:
Pheretima extract 25 parts, Folium Bambosae flavone 10 parts, Fructus Crataegi extract 3 parts, Radix Puerariae extract 1 part, Radix Ginseng extract 0.5 part, green tea extract 0.5 part, oligochitosan 8 parts and erythritol 52 parts.
Preparation method is similar to Example 1, adds corresponding adjuvant and makes tablet.
comparative example 2,
Prescription:
Natto extract 17 parts, Pheretima extract 16 parts, Folium Bambosae flavone 10 parts, Fructus Crataegi extract 3 parts, Radix Puerariae extract 1 part, Radix Ginseng extract 0.5 part, green tea extract 0.5 part and erythritol 52 parts.
Preparation method is similar to Example 1, adds corresponding adjuvant and makes tablet.
test example one,a kind of enzyme assay test with the medicine-food dual-purpose composition of hypolipemic function
1, test material: the medicine-food dual-purpose composition with hypolipemic function of embodiment 3, embodiment 4, embodiment 5 preparation.
2, test method: the method with reference to " health food inspection and assessment technical specification " (2003 editions) measures the enzymatic activity with nattokinase and Lumbrukinase in the medicine-food dual-purpose composition of hypolipemic function of embodiment 3, embodiment 4, embodiment 5 preparation.
3, result of the test
Result of the test is as shown in table 1.
One kind, table 1 has the enzyme assay test of the medicine-food dual-purpose composition of hypolipemic function
| 1. | 2. Embodiment 3 | 3. Embodiment 4 | 4. Embodiment 5 |
| 5. Nattokinase (FU/g) | 6. 2000 | 7. 2600 | 8. 4000 |
| 9. Lumbrukinase (FU/g) | 10. 5000 | 11. 6000 | 12. 10000 |
test example two,the medicine-food dual-purpose composition with hypolipemic function is tested the impact of hyperlipemia rat blood fat
1, test material: the medicine-food dual-purpose composition tablet with hypolipemic function of embodiment 4, comparative example 1 and comparative example 2 preparation.
2, subjects: choose male Waster rat 50, the age is about 6 week age, purchased from Beijing University's medical college Experimental Animal Center.
3, test method:
After 50 rats are normally raised 7 days with normal feedstuff, get Mus tail blood, detect the blood fat of rat, by TC level, animal is divided at random matched group, model group, test 1 group, tests 2 groups and test 3 groups, except control group fed normal feedstuff, all the other rats are fed high lipid food (high lipid food: normal feedstuff 78.8%, Adeps Sus domestica 10%, cholesterol 1%, yolk powder 10%, cholate 0.2%), each group dosage is as follows:
Matched group: the isopyknic normal saline of gavage;
Model group: the isopyknic normal saline of gavage;
Test the medicine-food dual-purpose composition tablet with hypolipemic function prepared by 1 group: gavage 2g/kg embodiment 4;
Test the medicine-food dual-purpose composition tablet with hypolipemic function prepared by 2 groups: gavage 2g/kg comparative example 1;
Test the medicine-food dual-purpose composition tablet with hypolipemic function prepared by 3 groups: gavage 2g/kg comparative example 2;
Successive administration 30 days, forbid rats eating after 30 days and weigh, fasting second day, gets the blood drawing of Mus tail, detects the TC (T-CHOL) of rat blood serum, TG (triglyceride), HDL-C(HDL-C respectively) and hemorheology of rat.
4, result of the test:
Result of the test is as shown in table 2 and table 3.
The content data of TC, TG and HDL-C of table 2 rats serum
| TC（mmol/L） | TG（mmol/L） | HDL-C（mmol/L） | |
| Matched group | 1.30±2.24 | 1.08±0.30 | 0.98±0.16 |
| Model group | 2.08±0.36 # | 1.86±0.38 # | 0.90±0.13 |
| Test 1 group | 1.31±0.22 ** | 0.90±0.26 ** | 0.97±0.15 |
| Test 2 groups | 1,89±0.35 | 1.35±0.34 | 0.93±0.14 |
| Test 3 groups | 1.86±0.34 | 1.28±0.33 | 0.92±0.14 |
Compared with matched group,
#p < 0.05; Compared with model group,
*p < 0.05,
*p < 0.01.
As shown in Table 2, after giving high lipid food, model group is compared with matched group, and Serum TC and TG level obviously increase, and shows the success of hyperlipidemia Animal Model.Compared with model group, test serum serum TC and TG content that 1 group extremely significantly can be reduced hyperlipemia rat (P < 0.01), prove that the medicine-food dual-purpose composition with hypolipemic function provided by the invention has lipid-lowering effect significantly.
Table 3 rat serum liquid stream change test data
| High shear viscosity (η/mpa.s -1） | In cut viscosity (η/mpa.s -1） | Low shear viscosity (η/mpa.s -1） | |
| Matched group | 1.84±0.25 | 1.60±0.26 | 1.40±0.36 |
| Model group | 2.84±0.34 ## | 2.20±0.30 # | 2.36±0.40 ## |
| Test 1 group | 1.40±0.18 ** | 1.32±0.20 ** | 1.48±0.35 ** |
| Test 2 groups | 1.95±0.26 * | 1.72±0.26 | 2.08±0.37 |
| Test 3 groups | 1.86±0.24 * | 1.58±0.25 * | 1.90±0.36 |
Compared with matched group,
#p < 0.05; Compared with model group,
*p < 0.05,
*p < 0.01.
Model group compared with matched group, hemorheology of rat high shear viscosity, in cut viscosity, low shear viscosity significantly increases, hyperlipidemia Animal Model success.Compared with model group, test 1 group can extremely significantly (P < 0.01) reduce hyperlipemia rat blood high shear viscosity, in cut viscosity and lowly cut viscosity, illustrate that medicine-food dual-purpose composition provided by the invention has fat-reducing effect significantly.
test example three,there is the clinical trial of the medicine-food dual-purpose composition of hypolipemic function
1, subjects: experimenter's inclusive criteria: experimenter is the crowd of non-simple dyslipidemia of being in hospital, voluntary participation.Duration of test keeps life on ordinary days and dietary habit, gets hematometry indices on an empty stomach.
Hyperlipidemia exception person 110 example, is divided into test group and matched group, number half and half.
2, criterion
Blood sampling twice in half a year, if the T-CHOL of secondary (TC)≤5.20mmol/L (200mg/dl) or
(TG)≤1.65mmol/L (150mg/dl) all can be used as alternative objects to triglyceride.
3, instructions of taking: test group takes the tablet with lipid-reducing function prepared by embodiment 4, oral each 1 time of morning every day, evening, each 1.2g; Matched group takes blank comfort sheet, oral each 1 time of morning every day, evening, each 1.2g.
4, efficacy assessments standard
Effective: T-CHOL reduces >10%, triglyceride (TG) reduces >15% value; HDL-C rising >0.104mmol/L, human feeding trial result judges: serum total cholesterol, triglyceride binomial index are positive, HDL-C, not significantly lower than matched group, can judge that this given the test agent has auxiliary lipid-lowering function effect.An index positive in serum total cholesterol, triglyceride binomial index, HDL-C, not significantly lower than matched group, can judge that this given the test agent has auxiliary reduction serum total cholesterol or the effect of auxiliary reduction triglyceride.
Invalid: not reach effective standard person.
5, human experiment result
Result of the test is as shown in table 4.
Table 4 has the clinical test results of the medicine-food dual-purpose composition of hypolipemic function
| 13. | 14. Effectively (example) | 15. Invalid (example) | 16. Total effective rate (%) |
| 17. Test group | 18. 45 | 19. 10 | 20. 81.8% |
| 21. Matched group | 22. 55 | 23. 55 | 24. 0% |
As shown in Table 4, effective number of cases of test group reaches 45, and total effective rate is 81.8%, and the total effective rate of matched group is 0%, illustrate that medicine-food dual-purpose composition provided by the invention has lipid-lowering effect, for vast hypercalcinuria patient provides a kind of blood fat reducing healthcare food of determined curative effect.
Claims (8)
1. there is a medicine-food dual-purpose composition for hypolipemic function, it is characterized in that, comprise following component and parts by weight thereof:
Natto extract 10-20 part, Pheretima extract 10-20 part, Folium Bambosae flavone 8-16 part, Fructus Crataegi extract 2-6 part,
Radix Puerariae extract 0.5-3 part, Radix Ginseng extract 0.1-2 part, green tea extract 0.1-2 part, oligochitosan 4-14 part and sweet
Taste agent 40-60 part.
2. there is the medicine-food dual-purpose composition of hypolipemic function as claimed in claim 1, it is characterized in that, comprise following component and parts by weight thereof:
Natto extract 13 parts, Pheretima extract 12 parts, Folium Bambosae flavone 10 parts, Fructus Crataegi extract 3 parts, Radix Puerariae extract 1 part, Radix Ginseng extract 0.5 part, green tea extract 0.5 part, oligochitosan 8 parts and sweeting agent 52 parts.
3. have the medicine-food dual-purpose composition of hypolipemic function as claimed in claim 1 or 2, it is characterized in that, the preparation method of described natto extract is:
S1 adds Semen sojae atricolor weight 2-4 times of water soaking 10-16h after being cleaned by Semen sojae atricolor;
The Semen sojae atricolor subpackage that step S1 obtains by S2, sterilizing 30min under 105 DEG C of conditions, accesses the bacillus subtilis of above-mentioned Semen sojae atricolor amount 0.5-2%, stirs, then at temperature is 37-39 DEG C, cultivate 35-45h, obtain natto when rear product temperature subject to sterilization is cooled to 30-35 DEG C;
Physiological saline solution joins in the natto that step S2 obtains by S3 under the aseptic condition of 25 DEG C-30 DEG C, the addition of normal saline be the 1-2 of natto weight doubly, stir 25-35min, filter, obtain eluent;
S4 by concentration be the eluent that obtains of ascorbic acid solution and the step S3 of 2-8% by volume 1:1 mix, adjust ph is to 7.0-7.2, pre-freeze 5-7h at being placed in-8 ~-6 DEG C, then put into temperature and be-45 DEG C, vacuum is 10-15Pa, and heating shelf temperature is in 30 DEG C of dry machines frozen after dry 10-20h, pulverizes under the aseptic condition of 0-8 DEG C, cross 40-80 order, to obtain final product.
4. have the medicine-food dual-purpose composition of hypolipemic function as claimed in claim 1 or 2, it is characterized in that, the preparation method of described Pheretima extract is:
Lumbricus is cleaned by S1, and adding pressure is that after placing 3-5h in the pressure reduction vessel of 90-95kPa, cleaning drains;
Adding above-mentioned Lumbricus weight 3-5 times concentration in the Lumbricus that S2 obtains toward step S1 is the sodium chloride solution of 0.5-2%, after then stirring 3-6min in refiner, leaves standstill 3-5h, obtains homogenate;
It is centrifugal 8-12min in the centrifuge of 9000-10000rpm that the homogenate that step S2 obtains by S3 adds rotating speed, stay supernatant, by the ultrafilter membrane of supernatant by molecular cut off 8k, it is-60 DEG C ~-70 DEG C in temperature, vacuum is freezing 2-4h under 15-20pa condition, then be 40-50 DEG C of dry 10-12h in temperature, obtain final product.
5. have the medicine-food dual-purpose composition of hypolipemic function as claimed in claim 1 or 2, it is characterized in that, described sweeting agent is one in Sorbitol, erythritol, xylitol and hydroxyl isomaltulose or its mixture.
6. have the medicine-food dual-purpose composition of hypolipemic function as claimed in claim 1 or 2, it is characterized in that, described compositions makes tablet, capsule, pill, granule or powder.
7. one kind as arbitrary in claim 1-6 as described in the preparation method with the medicine-food dual-purpose composition of hypolipemic function, it is characterized in that, comprise the following steps: S1 is by natto extract, Pheretima extract, Fructus Crataegi extract, Radix Puerariae extract, Radix Ginseng extract and green tea extract mix homogeneously, cross 18-25 mesh sieve, obtain mixing fine powders;
S2 adds Folium Bambosae flavone, oligochitosan and sweeting agent mix homogeneously toward the mixing fine powders that step S1 obtains, and to obtain final product.
8. the medicine-food dual-purpose composition as claimed in claim 1 or 2 with hypolipemic function is preparing the application had in the health food of effect for reducing blood fat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510913579.5A CN105343636B (en) | 2015-12-12 | 2015-12-12 | A kind of medicine-food dual-purpose composition and preparation method thereof with hypolipemic function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510913579.5A CN105343636B (en) | 2015-12-12 | 2015-12-12 | A kind of medicine-food dual-purpose composition and preparation method thereof with hypolipemic function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105343636A true CN105343636A (en) | 2016-02-24 |
| CN105343636B CN105343636B (en) | 2019-01-29 |
Family
ID=55319795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510913579.5A Active CN105343636B (en) | 2015-12-12 | 2015-12-12 | A kind of medicine-food dual-purpose composition and preparation method thereof with hypolipemic function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105343636B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770843A (en) * | 2016-05-13 | 2016-07-20 | 柯青 | Health-care pharmaceutical composition for heart and cerebral vessels |
| CN106474219A (en) * | 2016-11-11 | 2017-03-08 | 天津蚓福生物科技开发有限公司 | Blood fat reducing pressed candy |
| CN106563119A (en) * | 2016-11-11 | 2017-04-19 | 广州蛭肽素医药科技有限公司 | Pharmaceutical/food two-purpose composition capable of reducing blood fat, and preparation method thereof |
| CN109275817A (en) * | 2018-08-02 | 2019-01-29 | 江门桑科氏生物技术有限公司 | A kind of preparation method of the non-alcoholic fruit wine rich in Lovastain |
| CN109645464A (en) * | 2019-01-10 | 2019-04-19 | 蕴彤本草(北京)生物科技有限公司 | With blood activating and fat reducing thrombolysis and stroke rehabilitation effect composite nutrient and preparation method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102433316A (en) * | 2011-11-27 | 2012-05-02 | 甘肃华羚生物技术研究中心 | Preparation method for lumbrokinase dry powder |
| CN102716471A (en) * | 2012-07-03 | 2012-10-10 | 童长虹 | Anti-hyperlipidemia health-care product |
| CN103223033A (en) * | 2013-05-22 | 2013-07-31 | 武汉真福医药科技发展有限公司 | Novel natto health-care composite and preparation method and application thereof |
-
2015
- 2015-12-12 CN CN201510913579.5A patent/CN105343636B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102433316A (en) * | 2011-11-27 | 2012-05-02 | 甘肃华羚生物技术研究中心 | Preparation method for lumbrokinase dry powder |
| CN102716471A (en) * | 2012-07-03 | 2012-10-10 | 童长虹 | Anti-hyperlipidemia health-care product |
| CN103223033A (en) * | 2013-05-22 | 2013-07-31 | 武汉真福医药科技发展有限公司 | Novel natto health-care composite and preparation method and application thereof |
Non-Patent Citations (6)
| Title |
|---|
| 李书国: "《保健食品加工工艺与配方》", 28 April 2001, 科学技术文献出版社 * |
| 杨玉红等: "《生物技术概论》", 31 August 2011, 武汉理工大学出版社 * |
| 樊蔚虹: "《高血脂饮食养生宝典》", 31 December 2012, 陕西科学技术出版社 * |
| 陈耀华: "《人类健康的金钥匙—壳寡糖》", 31 August 2008, 中国医药科技出版社 * |
| 魏益民: "《21世纪中国食品与农业科学技术讨论会论文集》", 31 December 1999, 陕西人民出版社 * |
| 龚文华: "《临床糖尿病学》", 31 May 2014, 浙江工商大学出版社 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770843A (en) * | 2016-05-13 | 2016-07-20 | 柯青 | Health-care pharmaceutical composition for heart and cerebral vessels |
| CN106474219A (en) * | 2016-11-11 | 2017-03-08 | 天津蚓福生物科技开发有限公司 | Blood fat reducing pressed candy |
| CN106563119A (en) * | 2016-11-11 | 2017-04-19 | 广州蛭肽素医药科技有限公司 | Pharmaceutical/food two-purpose composition capable of reducing blood fat, and preparation method thereof |
| CN109275817A (en) * | 2018-08-02 | 2019-01-29 | 江门桑科氏生物技术有限公司 | A kind of preparation method of the non-alcoholic fruit wine rich in Lovastain |
| CN109645464A (en) * | 2019-01-10 | 2019-04-19 | 蕴彤本草(北京)生物科技有限公司 | With blood activating and fat reducing thrombolysis and stroke rehabilitation effect composite nutrient and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105343636B (en) | 2019-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105343636A (en) | Dual-purpose medical and edible composition with blood fat reducing function and preparing method of dual-purpose medical and edible composition | |
| CN106605909A (en) | Composition capable of relaxing the bowels, expelling toxin and preventing constipation, as well as preparation method thereof | |
| KR101738912B1 (en) | Composition For Anti-obesity And Diet | |
| CN110447902B (en) | Composition with weight-losing effect | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN105412277A (en) | Traditional Chinese medicinal composition of lipid-lowering tea and application of traditional Chinese medicinal composition | |
| CN106176952A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja and Folium Ilicis | |
| CN104305193B (en) | Food having effect of promoting intestine propulsion and preparation method of food | |
| CN110404042A (en) | A kind of compound oral liquid and preparation method thereof with fat reducing and weight reducing function | |
| CN108450941A (en) | A kind of dietary composition adjusting lipid metaboli | |
| CN104304586A (en) | Lipid-lowering tea bag and preparation method thereof | |
| CN113925172A (en) | Giant salamander peptide nutritional composition suitable for children | |
| CN104547013A (en) | Oral liquid for treating gastric mucosa and liver injury and preparation method of oral liquid | |
| CN107753602A (en) | A kind of Chinese medicine composition for treating leukaemia and preparation method thereof | |
| CN111888422A (en) | Preparation for reducing high blood pressure, high blood sugar and high blood fat and preparation method thereof | |
| CN104606571A (en) | Fresh spinach root tea substituted drink with effects of helping produce saliva and slaking thirst and preparation method thereof | |
| CN104474337A (en) | Preparation method of Chinese patent health granule containing green tea extract | |
| CN109925451A (en) | A kind of lower blood-fat and reduce weight tea-drinking | |
| CN104188021A (en) | Mung bean toxicity-removing and liver-protecting health-care beverage and production method thereof | |
| CN106343094A (en) | Healthcare tea for strengthening waist and knee and benefiting essence and blood | |
| CN102145125B (en) | Propolis and aweto capsule for treating diabetes | |
| CN108260815A (en) | It is a kind of have the function of reducing blood lipid, weight-reducing health food and preparation method thereof | |
| CN106563119A (en) | Pharmaceutical/food two-purpose composition capable of reducing blood fat, and preparation method thereof | |
| CN100496565C (en) | Chinese medicine decoction for treating hypertension | |
| CN106387571A (en) | Health-care beverage containing persimmon leaves and persimmon fruits, and preparation method of health-care beverage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a medicinal and edible composition with blood lipid lowering function and a preparation method thereof Effective date of registration: 20220623 Granted publication date: 20190129 Pledgee: Agricultural Bank of China Limited Guangdong pilot Free Trade Zone Nansha branch Pledgor: GUANGDONG ZHENGDANGNIAN BIOTECHNOLOGY CO.,LTD. Registration number: Y2022980008726 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230802 Granted publication date: 20190129 Pledgee: Agricultural Bank of China Limited Guangdong pilot Free Trade Zone Nansha branch Pledgor: GUANGDONG ZHENGDANGNIAN BIOTECHNOLOGY CO.,LTD. Registration number: Y2022980008726 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A dual-purpose combination of medicine and food with lipid-lowering function and its preparation method Effective date of registration: 20230807 Granted publication date: 20190129 Pledgee: Agricultural Bank of China Limited Guangdong pilot Free Trade Zone Nansha branch Pledgor: GUANGDONG ZHENGDANGNIAN BIOTECHNOLOGY CO.,LTD. Registration number: Y2023980051113 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| CP03 | Change of name, title or address |
Address after: No.82, Dongchong Section, Shinan Road, Nansha District, Guangzhou, Guangdong Province, 515000 Patentee after: Guangdong Zhengnian Biotechnology Co.,Ltd. Country or region after: China Address before: No.82, Dongchong Section, Shinan Road, Nansha District, Guangzhou, Guangdong Province, 515000 Patentee before: GUANGDONG ZHENGDANGNIAN BIOTECHNOLOGY CO.,LTD. Country or region before: China |
|
| CP03 | Change of name, title or address |